United Laboratories International Holdings (HKG:3933) said its subsidiary's UBT251 drug received approval from the US Food and Drug Administration for a Phase II clinical trial targeting chronic kidney disease (CKD), according to a Monday filing with the Hong Kong Exchange.
Based on the preclinical obesity/diabetic nephropathy pharmacodynamic model, UBT251
demonstrated "significantly superior overall improvement effects on renal urinary albumin and
other related renal injury markers and histopathology than Semaglutide," United Laboratories said.
UBT251, developed by United Laboratories subsidiary The United Bio-Technology (Hengqin), received clinical trial authorization in China in January for the same indication.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。